Enflonsia (Clesrovimab) Now Available Through VFC
On June 9, 2025, the Food and Drug Administration (FDA) licensed Merck’s Enflonsia (clesrovimab) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract infection (LRTI).On June 26, 2025, the Advisory Committee on Immunization Practices(ACIP) voted to recommend clesrovimab for use in infants younger than...